摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl (2,3-di-O-methyl-α-D-glucopyranosyl)-(1->4)-2,3-di-O-methyl-1-thio-β-D-glucopyranoside | 202647-73-2

中文名称
——
中文别名
——
英文名称
ethyl (2,3-di-O-methyl-α-D-glucopyranosyl)-(1->4)-2,3-di-O-methyl-1-thio-β-D-glucopyranoside
英文别名
Glc2Me3Me(a1-4)Glc2Me3Me(b)-SEt;(2R,3R,4S,5R,6R)-6-[(2R,3R,4S,5R,6S)-6-ethylsulfanyl-2-(hydroxymethyl)-4,5-dimethoxyoxan-3-yl]oxy-2-(hydroxymethyl)-4,5-dimethoxyoxan-3-ol
ethyl (2,3-di-O-methyl-α-D-glucopyranosyl)-(1->4)-2,3-di-O-methyl-1-thio-β-D-glucopyranoside化学式
CAS
202647-73-2
化学式
C18H34O10S
mdl
——
分子量
442.528
InChiKey
XJECGYCURIESBH-TXSAWVTMSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.9
  • 重原子数:
    29
  • 可旋转键数:
    10
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    151
  • 氢给体数:
    3
  • 氢受体数:
    11

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    ethyl (2,3-di-O-methyl-α-D-glucopyranosyl)-(1->4)-2,3-di-O-methyl-1-thio-β-D-glucopyranoside4-二甲氨基吡啶盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下, 以 1,4-二氧六环1,2-二氯乙烷 为溶剂, 反应 3.5h, 生成 ethyl (6-O-acetyl-4-O-levulinyl-2,3-di-O-methyl-α-D-glucopyranosyl)-(1->4)-6-O-acetyl-2,3-di-O-methyl-1-thio-β-D-glucopyranoside
    参考文献:
    名称:
    Synthetic Carbohydrate Derivatives as Low Sulfated Heparin Mimetics
    摘要:
    The total synthesis of a new family of heparin mimetics containing an hexadeca- (2), an octadeca- (3), and an eicosasaccharide (4) is described. All three oligosaccharides contain a pentasaccharidic antithrombin binding domain(DEFGH: van Boeckel, C. A. A.; Petitou, M. Angew. Chem., Int. Ed. Engl. 1993, 32, 1671-1690), extended at the nonreducing end by a thrombin binding domain composed of repeated 2,3-di-O-methyl-6-O-sodium sulfonato-alpha-D-glucosyl units, The targets were synthesized using a key dodecasaccharide imidate as glycosyl donor as well as di- and tetrasaccharide imidates, all derived from maltose. Condensation of these imidates with a tetrasaccharide precursor of the EFGH part of the antithrombin binding domain gave fully protected hexadeca-, octadeca-, and eicosasaccharide that were deprotected and sulfated to yield 2, 3, and 4. All three displayed antithrombin-mediated antifactor Xa and antithrombin (factor IIa) activity. The most active compound, the eicosasaccharide, showed activity similar to that of low molecular weight heparin. Significantly, unlike heparin and its derivatives, the present: heparin mimetics do not interact with platelet factor 4, an interaction that can cause severe side effects in heparin-treated patients. Thus, this new family of compounds contains interesting drug candidates for the prevention and treatment of thrombosis.
    DOI:
    10.1021/jo991152j
  • 作为产物:
    参考文献:
    名称:
    Synthetic Carbohydrate Derivatives as Low Sulfated Heparin Mimetics
    摘要:
    The total synthesis of a new family of heparin mimetics containing an hexadeca- (2), an octadeca- (3), and an eicosasaccharide (4) is described. All three oligosaccharides contain a pentasaccharidic antithrombin binding domain(DEFGH: van Boeckel, C. A. A.; Petitou, M. Angew. Chem., Int. Ed. Engl. 1993, 32, 1671-1690), extended at the nonreducing end by a thrombin binding domain composed of repeated 2,3-di-O-methyl-6-O-sodium sulfonato-alpha-D-glucosyl units, The targets were synthesized using a key dodecasaccharide imidate as glycosyl donor as well as di- and tetrasaccharide imidates, all derived from maltose. Condensation of these imidates with a tetrasaccharide precursor of the EFGH part of the antithrombin binding domain gave fully protected hexadeca-, octadeca-, and eicosasaccharide that were deprotected and sulfated to yield 2, 3, and 4. All three displayed antithrombin-mediated antifactor Xa and antithrombin (factor IIa) activity. The most active compound, the eicosasaccharide, showed activity similar to that of low molecular weight heparin. Significantly, unlike heparin and its derivatives, the present: heparin mimetics do not interact with platelet factor 4, an interaction that can cause severe side effects in heparin-treated patients. Thus, this new family of compounds contains interesting drug candidates for the prevention and treatment of thrombosis.
    DOI:
    10.1021/jo991152j
点击查看最新优质反应信息

文献信息

  • Synthetic Carbohydrate Derivatives as Low Sulfated Heparin Mimetics
    作者:Pierre-A. Driguez、Isidore Lederman、Jean-M. Strassel、Jean-M. Herbert、Maurice Petitou
    DOI:10.1021/jo991152j
    日期:1999.12.1
    The total synthesis of a new family of heparin mimetics containing an hexadeca- (2), an octadeca- (3), and an eicosasaccharide (4) is described. All three oligosaccharides contain a pentasaccharidic antithrombin binding domain(DEFGH: van Boeckel, C. A. A.; Petitou, M. Angew. Chem., Int. Ed. Engl. 1993, 32, 1671-1690), extended at the nonreducing end by a thrombin binding domain composed of repeated 2,3-di-O-methyl-6-O-sodium sulfonato-alpha-D-glucosyl units, The targets were synthesized using a key dodecasaccharide imidate as glycosyl donor as well as di- and tetrasaccharide imidates, all derived from maltose. Condensation of these imidates with a tetrasaccharide precursor of the EFGH part of the antithrombin binding domain gave fully protected hexadeca-, octadeca-, and eicosasaccharide that were deprotected and sulfated to yield 2, 3, and 4. All three displayed antithrombin-mediated antifactor Xa and antithrombin (factor IIa) activity. The most active compound, the eicosasaccharide, showed activity similar to that of low molecular weight heparin. Significantly, unlike heparin and its derivatives, the present: heparin mimetics do not interact with platelet factor 4, an interaction that can cause severe side effects in heparin-treated patients. Thus, this new family of compounds contains interesting drug candidates for the prevention and treatment of thrombosis.
查看更多